View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 21, 2020

Alexion to study Ultomiris for Covid-19 treatment

Alexion Pharmaceuticals intends to assess its blood disorder drug Ultomiris (ravulizumab-cwvz) to treat adult Covid-19 patients hospitalised with severe pneumonia or acute respiratory distress syndrome (ARDS).

The US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for the drug in severe Covid-19 indication.

Ultomiris is a long-acting C5 complement inhibitor. The biologic medicine has approvals to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and complement-mediated thrombotic microangiopathy.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena